Best of ASCO 2023 Annual Meeting
  1. Página Inicial

Programação

Filtrar atividades
Plenária
15:00 - 17:00 Módulo

Módulo Pulmão/Novas terapias

15:00 - 15:07
Abstract 2503
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
15:07 - 15:15
LBA100
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
15:15 - 15:22
LBA3
OS survival analysis from the ADURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIA NSCLC.
15:22 - 15:30
LBA8505
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
non-squamous, non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L).
15:30 - 16:00
Intervalo
16:00 - 16:07
LBA9000
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
16:07 - 16:15
Abstract 9004
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
16:15 - 16:23
LBA9005
Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.
16:23 - 16:30
Abstract 9006
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in advanced
16:30 - 17:00
Discussão